Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Bayer HealthCare Pharmaceuticals has announced that the FDA has approved Eovist injection, a gadolinium-based contrast agent, for intravenous use in T1-weighted magnetic resonance imaging of the liver to detect and characterize lesions in adults with known or suspected focal liver disease.
Subscribe to our email newsletter
Bayer HealthCare’s Eovist is a paramagnetic MRI contrast agent that combines features of both an extracellular contrast agent and a hepatocyte-specific agent. The approval makes Eovist the first organ-specific magnetic resonance imaging (MRI) contrast agent approved in the US in more than a decade.
Eovist is administered via an intravenous, bolus injection and has a dual route of excretion with approximately 50% eliminated through the liver and 50% eliminated through the kidney. Detection and characterization of malignant and benign focal liver lesions with Eovist may help enhance diagnostic accuracy and increase diagnostic confidence.
Douglas Stefanelli, vice president and general manager of diagnostic imaging at Bayer HealthCare, said: “The approval of Eovist in the US marks a significant achievement in advancing the accurate diagnosis of liver disease.”